{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:25:09Z","timestamp":1773282309969,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/iae.0b013e3181c9691e","type":"journal-article","created":{"date-parts":[[2010,2,27]],"date-time":"2010-02-27T06:03:35Z","timestamp":1267250615000},"page":"407-412","source":"Crossref","is-referenced-by-count":58,"title":["INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION"],"prefix":"10.1097","volume":"30","author":[{"given":"RUFINO M.","family":"SILVA","sequence":"first","affiliation":[]},{"given":"JOS\u00c9 M.","family":"RUIZ-MORENO","sequence":"additional","affiliation":[]},{"given":"PAULO","family":"ROSA","sequence":"additional","affiliation":[]},{"given":"\u00c2NGELA","family":"CARNEIRO","sequence":"additional","affiliation":[]},{"given":"JO\u00c3O","family":"NASCIMENTO","sequence":"additional","affiliation":[]},{"given":"LU\u00cdS F.","family":"RITO","sequence":"additional","affiliation":[]},{"given":"M. LUZ","family":"CACHULO","sequence":"additional","affiliation":[]},{"given":"FAUSTO","family":"CARVALHEIRA","sequence":"additional","affiliation":[]},{"given":"JOAQUIM N.","family":"MURTA","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-4-20210130","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0161-6420(84)34116-1","article-title":"Natural history of choroidal neovascularization in degenerative myopia.","volume":"91","author":"Avila","year":"1984","journal-title":"Ophthalmology"},{"key":"R2-4-20210130","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0161-6420(83)80018-9","article-title":"Visual prognosis of disciform degeneration in myopia.","volume":"90","author":"Hampton","year":"1983","journal-title":"Ophthalmology"},{"key":"R3-4-20210130","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0161-6420(99)90484-0","article-title":"Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization.","volume":"106","author":"Tabandeh","year":"1999","journal-title":"Ophthalmology"},{"key":"R4-4-20210130","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0161-6420(01)01007-7","article-title":"Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups.","volume":"109","author":"Yoshida","year":"2002","journal-title":"Ophthalmology"},{"key":"R5-4-20210130","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularisation in pathologic myopia: 2-year results of a randomized clinical trial\u2014VIP report no. 3.","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"key":"R6-4-20210130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bjo.87.2.173","article-title":"Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.","volume":"87","author":"Montero","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R7-4-20210130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ajo.2006.11.037","article-title":"Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study.","volume":"143","author":"Pece","year":"200","journal-title":"Am J Ophthalmol"},{"key":"R8-4-20210130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"key":"R9-4-20210130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.","volume":"147","author":"Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R10-4-20210130","first-page":"707","article-title":"Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.","volume":"27","author":"Hernandez-Rojas","year":"2007","journal-title":"Retina"},{"key":"R11-4-20210130","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.eye.6703052","article-title":"Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.","volume":"23","author":"Ruiz-Moreno","year":"2009","journal-title":"Eye (Lond)"},{"key":"R12-4-20210130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bjo.2006.101337","article-title":"Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.","volume":"91","author":"Rosenfeld","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R13-4-20210130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","article-title":"Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.","volume":"147","author":"Gharbiya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R14-4-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R15-4-20210130","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization. Six-month results of a prospective pilot study.","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"R16-4-20210130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IAE.0b013e31817eda41","article-title":"Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularisation.","volume":"28","author":"Silva","year":"2008","journal-title":"Retina"},{"key":"R17-4-20210130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R18-4-20210130","first-page":"361","article-title":"Ranibizumab: phase III clinical trial results.","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006982-201003000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:23:54Z","timestamp":1618277034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201003000-00004"}},"subtitle":["12-Month Results"],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3181c9691e","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}